Product Images Gabapentin

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 7 images provide visual information about the product associated with Gabapentin NDC 68788-8199 by Preferred Pharmaceuticals Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Gabapentin Capsules 100mg - 6ECF5114 2DDC 4025 A36D 1884702DC22A 00

Gabapentin Capsules 100mg - 6ECF5114 2DDC 4025 A36D 1884702DC22A 00

This is a description of Gabapentin Capsules 100mg, a medication used for treatment of several conditions, including seizures and nerve damage. The drug is available in capsule form, with each capsule containing 100mg of Gabapentin. The packaging information reveals the expiration date, the lot number, as well as the manufacturer's details. It is important to note that transferring this medication to anyone other than the person for whom it was prescribed is prohibited by federal law. The packaging also advises keeping this medication out of reach for children. It's unclear what "Billing Chart Log" refers to.*

formula - ab1e0185 b802 4cf2 a5d4 b71f27f1dcb0 00

formula - ab1e0185 b802 4cf2 a5d4 b71f27f1dcb0 00

This formula calculates the estimated creatinine clearance (ClCr) for patients based on their age, weight, and serum creatinine levels. The formula is adjusted for female patients by multiplying the result by 0.85.*

figure1 - d45f499b 8612 479e 8dd2 4fe28b1f5f9c 01

figure1 - d45f499b 8612 479e 8dd2 4fe28b1f5f9c 01

image 1 - d45f499b 8612 479e 8dd2 4fe28b1f5f9c 02

image 1 - d45f499b 8612 479e 8dd2 4fe28b1f5f9c 02

image 2 - d45f499b 8612 479e 8dd2 4fe28b1f5f9c 03

image 2 - d45f499b 8612 479e 8dd2 4fe28b1f5f9c 03

This appears to be a table or chart showing a 4 week fixed dose period with three different treatments: placebo, Gabapentin at 1800 mg/day, and Gabapentin at 2400 mg/day. The chart also includes a "mean pain score" measured at baseline and weeks 1 through 7. Without more information, it is unclear what condition or population this data pertains to.*

image 3 - d45f499b 8612 479e 8dd2 4fe28b1f5f9c 04

image 3 - d45f499b 8612 479e 8dd2 4fe28b1f5f9c 04

The text describes a figure (Figure 3) showing the percentage of patients with a greater than 50% reduction in pain score (responders) in studies evaluating the effectiveness of a medication for controlled PHN (Postherpetic neuralgia). The text provides the percentages for two studies (Study 1 and Study 2) and shows that Study 2 had higher response rates compared to Study 1. There is also a reference to a statistical significance (p<0.001) and the cost of the medication (GBP 800 and GBP 2400).*

image 4 - d45f499b 8612 479e 8dd2 4fe28b1f5f9c 05

image 4 - d45f499b 8612 479e 8dd2 4fe28b1f5f9c 05

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.